Cyclooxygenase-2 Expression in Periampullary Cancer.
- Author:
Young Jin CHOI
1
;
Guang Bi JIN
;
Lee Chan JANG
;
Jin Woo PARK
;
Rohyun SUNG
;
Jae Woon CHOI
Author Information
1. Department of Surgery, Chungbuk National University Medical School, Cheongju, Korea. jwchoi@med.chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
Cyclooxygenase-2;
Periampullary cancer
- MeSH:
Adenocarcinoma;
Ampulla of Vater;
Carcinogenesis;
Common Bile Duct;
Cyclooxygenase 2 Inhibitors;
Cyclooxygenase 2*;
Humans;
Ink;
Neoplasm Metastasis
- From:Journal of the Korean Surgical Society
2003;65(1):49-54
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Cyclooxygenase-2 (COX-2) expression is up-regulated in several types of human cancers and it has been suggested that COX-2 is closely inked to carcinogenesis. The objectives of this study were to investigate COX-2 expression in periampullary cancer and to evaluate the association of the clinicopathological factors with its expression. METHODS: Thirty specimens which were resected from patients with periampullary cancers (13 pancreatic adenocarcinomas, 8 common bile duct cancers, 9 ampulla of vater cancers) were investigated by immunohistochemical staining using Anti COX-2 monoclonal Ab. The 30 specimens were divided into stain-positive and stain-negative groups. The correlation between COX-2 expression and the various clinicopathological factors including the tumor size, nodal metastasis, differentiation, perineural and vascular invasion, were studied. RESULTS: COX-2 was expressed in 69% of pancreatic adenocarcinomas, 100% of common bile duct cancers and 78% of ampulla of vater cancers. However there was no significant correlation between COX-2 expression and the clinicopathological factors. CONCLUSION: COX-2 is highly expressed in periampullary cancer. Even though there was no correlation with the clinicopathological factors, the utility of the COX-2 inhibitors in preventing or treating periampullary cancer remains undetermined but warronts further investigation.
